RxDoctor Payments Data

Matthew Sewell, MD

Cardiovascular Disease · Paoli, PANPI 1164467452

Payments from drug & device makers

$586in general payments, 2019–2025

Across 29 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$159
  • Novartis$71
  • Medtronic$60
  • Boehringer Ingelheim$58
  • Pfizer$48
  • Impulse Dynamics (USA) Inc.$41
  • plus $149 from 7 others

What the payments were for

  • Food & beverage$586100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$586 in reported general payments places this provider in the 25th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,000,681
Medicare patients
2,026
Services billed
7,996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban587$722,260
XareltoRivaroxaban193$218,313
Repatha SureclickEvolocumab78$82,237
EntrestoSacubitril/Valsartan52$55,044
MultaqDronedarone Hcl25$42,336
JardianceEmpagliflozin19$26,042
Praluent PenAlirocumab25$16,124
Rosuvastatin Calcium834$13,873
Metoprolol Succinate821$13,496
Dabigatran EtexilateDabigatran Etexilate Mesylate35$12,387
BrilintaTicagrelor13$11,137
Nebivolol Hcl145$8,470
FarxigaDapagliflozin Propanediol12$8,035
Dofetilide23$7,281
Valsartan200$7,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$48$722,260587 claims
Johnson & JohnsonXarelto$17$218,313193 claims
NovartisEntresto$71$55,04452 claims
Boehringer IngelheimJardiance$58$26,04219 claims
AstraZenecaBrilinta, Farxiga$13$19,17225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Paoli

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →